Bain Capital and Cinven have signed a definitive agreement to sell a majority stake in STADA Arzneimittel AG to CapVest Partners, marking a pivotal step in the company's growth trajectory within the global healthcare market.

Information on the Target

STADA Arzneimittel AG, a prominent pharmaceutical company based in Germany, specializes in the production and distribution of generics, specialty pharmaceuticals, and consumer healthcare products. Since its privatisation by Bain Capital and Cinven in 2017, STADA has undergone a significant transformation, evolving from a traditional generics provider into a diversified global healthcare powerhouse. Under the guidance of its management team, STADA has successfully expanded its operations, achieving revenues exceeding €4 billion and a compound annual net sales growth rate of 9%, while also more than doubling its EBITDA since the acquisition.

During Bain and Cinven's ownership, STADA executed over 25 targeted acquisitions, enhancing its market position across Europe and beyond. Notable acquisitions include the Johnson & Johnson Nizoral brand, Walmark, and a selection of consumer healthcare brands from GlaxoSmithKline and Sanofi, which further solidified STADA’s footprint in the international market.

Industry Overview in Germany

The German pharmaceuticals industry is one of the largest and most influential in Europe, with a strong focus on innovation, research, and development. It benefits from a robust regulatory framework and is supported by a